NL7104752A - Anti-alcoholic compsns contng calcium 5-buty - Google Patents

Anti-alcoholic compsns contng calcium 5-buty

Info

Publication number
NL7104752A
NL7104752A NL7104752A NL7104752A NL7104752A NL 7104752 A NL7104752 A NL 7104752A NL 7104752 A NL7104752 A NL 7104752A NL 7104752 A NL7104752 A NL 7104752A NL 7104752 A NL7104752 A NL 7104752A
Authority
NL
Netherlands
Prior art keywords
calcium
alcoholic
contng
compsns
buty
Prior art date
Application number
NL7104752A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to NL7104752A priority Critical patent/NL7104752A/en
Publication of NL7104752A publication Critical patent/NL7104752A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anti-alcoholic compsn. comprise a carrier and, as active ingredient, calcium 5-butylpicolinate (I) or calcium 5-pentyl-picolinate (II), in an amount of 50-200 mg per unit does. (I) and (II) inhibit dopamine-beta-hydroxylase, and are pref. administered orally at the rate of 200-800 mg/day in three or four unit doses. They are non-irritant to the stomach and non-toxic to patients suffering from hypertension.
NL7104752A 1971-04-08 1971-04-08 Anti-alcoholic compsns contng calcium 5-buty NL7104752A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL7104752A NL7104752A (en) 1971-04-08 1971-04-08 Anti-alcoholic compsns contng calcium 5-buty

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7104752A NL7104752A (en) 1971-04-08 1971-04-08 Anti-alcoholic compsns contng calcium 5-buty

Publications (1)

Publication Number Publication Date
NL7104752A true NL7104752A (en) 1972-10-10

Family

ID=19812880

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7104752A NL7104752A (en) 1971-04-08 1971-04-08 Anti-alcoholic compsns contng calcium 5-buty

Country Status (1)

Country Link
NL (1) NL7104752A (en)

Similar Documents

Publication Publication Date Title
IE812232L (en) Composition
IE37378B1 (en) Taste-improving formulations of oral penicillins
IE42950L (en) X-ray contrast preparations
KR890003391A (en) Calcium supplements
NO137899C (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N (1H-TETRAZOL-5-YL) -KINAL DAMIDES
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
NL7104752A (en) Anti-alcoholic compsns contng calcium 5-buty
FR2132601A1 (en) Anti-alcoholic compsns contng calcium 5-buty
BE765809A (en) Anti-alcoholic compsns contng calcium 5-buty
JPS52108028A (en) Remedies for dysacousis
GB1118606A (en) Compositions for the treatment of haemorrhoids
Hall et al. ADVANCED NEOPLASTIC DISEASE—Treatment with 5-Fluorouracil and Irradiation
FR2081364A1 (en) Compsn for oral calcitherapy
EP0093497A3 (en) Anthelmintic treatment
ES8502332A1 (en) Galenic forms of sulpiride for oral administration.
US4216207A (en) Method and composition for treatment of gastro-duodenal ulcers
ES436179A1 (en) Physiological substances for intensifying the pharmacological effect of drugs
IE36780B1 (en) New pharmaceutical preparations
GB1437138A (en) Method of increasing sexual potency
REIMANN et al. Chloramphenicol in Paratyphoid A: Observations with a Note on the Clinical Aspects of the Disease
GB1424611A (en) Pharmaceutical compositions
GB1375806A (en)
DAVIS Thiabendazole in Pinworm Infestations: II. Comparison of Single and Intermittent Therapy, Long-Term Follow-Up, and Evaluation of New Dosage Form
FR2085730A1 (en) Salicylamide salts for oral administration
FR2059480A1 (en) Anticarcinogenic compns contng vitamin a - acids